---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015632"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:21:21.774160+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProMIS Q3 net income $9.3M, cash $21.5M; Phase 1a positive; PIPE up to $122.7M

## Summary
- Net income of $9.3M for Q3 2024 vs net loss of $2.4M YoY, driven by $17.0M gain on warrant liabilities.
- Cash and equivalents $21.5M at Sep 30, 2024, up from $12.6M at Dec 31, 2023.
- PIPE financing closed with initial $30.3M; potential additional $92.4M from warrant exercise.
- Phase 1a trial of PMN310 in Alzheimer's showed good tolerability, dose-dependent BBB crossing, supporting monthly dosing.
- Phase 1b clinical trial in AD patients on track to start by end of 2024.

## SEC filing metadata
- accession: 0001558370-24-015632
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837024015632/0001558370-24-015632-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837024015632/pmn-20241114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015632
- JSON: https://secwatch.observer/filing/0001558370-24-015632.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015632.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.